跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CINRYZE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CINRYZE
Authorized
STANDARD
CINRYZE
takeda canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f1863af9074219a1
Company
takeda canada inc
Type
Standard
Approval Details
Approval Id
f1863af9074219a1
Drug Approval Canada Name
CINRYZE
Product Name
CINRYZE
Status
Dormant
Status Date
2023-09-17
Original Market Date
2016-03-08
Din
02395371
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
92:32.00
Atc Original
B06AC01 C1-INHIBITOR, PLASMA DERIVED
Atc Name
b 06 ac 01
Aig Number
0152746001
Company Name
takeda canada inc
Company Address
3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3
Active Ingredients
C1 ESTERASE INHIBITOR (HUMAN)
500 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f1863af9074219a1
Type
Standard
Back to Health Canada Approvals